Springer Burkhard, Lucke Katja, Calligaris-Maibach Romana, Ritter Claudia, Böttger Erik C
Institut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, CH-8006 Zürich, Switzerland.
J Clin Microbiol. 2009 Jun;47(6):1773-80. doi: 10.1128/JCM.02501-08. Epub 2009 Apr 1.
Since numbers of drug-resistant Mycobacterium tuberculosis strains are on the rise, the simple classification into "susceptible" and "resistant" strains based on susceptibility testing at "critical concentrations" has to be reconsidered. While future studies have to address the correlation of phenotypic resistance levels and treatment outcomes, a prerequisite for corresponding investigations is the ability to exactly determine levels of quantitative drug resistance in clinical M. tuberculosis isolates. Here we have established the conditions for quantitative drug susceptibility testing for first- and second-line agents using MGIT 960 instrumentation and EpiCenter software equipped with the TB eXiST module. In-depth comparative analysis of a range of well-characterized susceptible and resistant clinical isolates has allowed us to propose conditions for testing and to develop criteria for interpretation.
由于耐药结核分枝杆菌菌株的数量在不断增加，基于“临界浓度”药敏试验将菌株简单分类为“敏感”和“耐药”的方法必须重新考虑。虽然未来的研究需要解决表型耐药水平与治疗结果之间的相关性，但相应研究的一个先决条件是能够准确测定临床结核分枝杆菌分离株的定量耐药水平。在此，我们利用配备了TB eXiST模块的MGIT 960仪器和EpiCenter软件，建立了一线和二线药物定量药敏试验的条件。对一系列特征明确的敏感和耐药临床分离株进行深入的比较分析，使我们能够提出检测条件并制定解释标准。
